For Institutions
About
Yum China Holdings Inc. disclosed the repurchase of 16,600 shares for HKD 6.27 million via HKEX. The repurchase was executed under a Rule 10b5-1 agreement. Details are in the company's announcement dated May 29, 2025. This AI-generated brief is for informational purposes and not financial advice.
Bristol-Myers Squibb (NYSE:BMY) offers Eliquis free to Medicaid patients under a new pricing pact. The company, along with other major US and European drugmakers, agreed with President Trump to voluntarily lower certain medicine prices. This initiative aligns with the administration's efforts to better align US drug prices with international standards.
MarketBeat highlights seven pharmaceutical stocks to watch: Novo Nordisk, Eli Lilly, Pfizer, Bristol Myers Squibb, AbbVie, Abbott Laboratories, and Gilead Sciences. These companies are noted for their high trading volumes and potential for substantial returns, driven by factors like clinical trial results and regulatory approvals. However, they also carry risks such as volatility and regulatory challenges. The report provides insights into each company's focus areas and recent developments.
Coca-Cola, McDonald's, Yum! Brands, and Yum China have all shown a Golden Cross pattern, indicating a shift in longer-term momentum. This technical pattern suggests a preference for stability and cash-flow visibility. Yum! Brands and Yum China are momentum leaders, McDonald's shows steady momentum, and Coca-Cola indicates a defensive reset. The market may be rotating towards durable brands and predictable demand.
Guggenheim's Seamus Fernandez maintained a Buy rating on Bristol-Myers Squibb with a $62 price target. The stock closed at $54.66. Fernandez, a 5-star analyst, has a 29.8% average return. Bristol-Myers also received a Buy from Bank of America Securities, while Bernstein rated it Hold. Fernandez covers the Healthcare sector, including Eli Lilly & Co and Cidara Therapeutics.
